ArticleBiochemistry2007
Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol.
Article in Biochemistry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis.Immunity, inflammation and disease · 2021Pooled it
- Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans.Antimicrobial agents and chemotherapy · 2013Trial
- Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers.Clinical therapeutics · 2009Trial
- Enhanced Antiviral Activity of Novel Umifenovir Derivatives against SARS-CoV-2: Insights from an International Collaborative Study.ACS omega · 2026Article
- Arbidol: The current demand, strategies, and antiviral mechanisms.Immunity, inflammation and disease · 2023Review
- Umifenovir Epigenetically Targets theMicrobiology spectrum · 2023Article
- Modeling the Structure-Activity Relationship of Arbidol Derivatives and Other SARS-CoV-2 Fusion Inhibitors Targeting the S2 Segment of the Spike Protein.Journal of chemical information and modeling · 2021Article
- Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs.Antimicrobial agents and chemotherapy · 2021Article
- Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations.European journal of pharmacology · 2021Article
- Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients.Cardiology discovery · 2021Article
- Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action.Biochemical pharmacology · 2021Review
- A Chemographic Audit of anti-Coronavirus Structure-activity Information from Public Databases (ChEMBL).Molecular informatics · 2020Article
- Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.Virus research · 2020Article
- A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19.Journal of medical virology · 2020Article
- Drug treatment of coronavirus disease 2019 (COVID-19) in China.European journal of pharmacology · 2020Review
- Approaches for the Treatment of SARS-CoV-2 Infection: A Pharmacologic View and Literature Review.Iranian journal of pharmaceutical research : IJPR · 2020Review
- Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.Journal of virology · 2019Article
- The Antiviral Drug Arbidol Inhibits Zika Virus.Scientific reports · 2018Article
- Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses.Viruses · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Hepatitis C affects approximately 3% of the world population, yet its current treatment options are limited to interferon-ribavirin drug regimens which achieve a 50-70% cure rate depending on the hepatitis C virus (HCV) genotype. Besides extensive screening for HCV-specific compounds, some well-established medicinal drugs have recently demonstrated an anti-HCV effect in HCV replicon cells. One of these drugs is arbidol (ARB), a Russian-made broad-spectrum antiviral agent, which we have previously shown to inhibit acute and chronic HCV infection. Here we show that ARB inhibits the cell entry of HCV pseudoparticles of genotypes 1a, 1b, and 2a in a dose-dependent fashion. ARB also displayed a dose-dependent inhibition of HCV membrane fusion, as assayed by using HCV pseudoparticles (HCVpp) and fluorescent liposomes. ARB inhibition of HCVpp fusion was found to be more effective on genotype 1a than on genotypes 1b and 2a. In vitro biochemical studies revealed association of ARB with membranelike environments such as detergents and with lipid membranes. This association was particularly prominent at acidic pH which is optimal for HCV-mediated fusion. Our results suggest that the affinity of ARB for lipid membranes could account for its anti-HCV actions, together with a differential level of interaction with key motifs in HCV glycoproteins of different genotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.